Perrigo Receives FDA Approval To Market Mini Nicotine Lozenges
ALLEGAN — The Perrigo Co. (Nasdaq: PRGO) announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications to market over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).
This ANDA approval represents the first approval for mini lozenge products that will be targeted for the store brand market. The mint flavored mini lozenge will be marketed under retailer and wholesalers’ store, or own brand labels and is comparable to GlaxoSmithKline’s Nicorette Mini Lozenge. The product is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.
“This approval strengthens Perrigo’s leading store brand position in smoking cessation products, which also includes coated and uncoated flavored gums and lozenges,” said Joseph C. Papa, Perrigo chairman, president and CEO.
Nicorette Mini Lozenge is selling at an annual rate estimated at over $30 million at all retail outlets.
The product is expected to begin shipping in the next 90 days.
Perrigo develops, manufactures and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia.
More at www.perrigo.com.